Abdi İbrahim Otsuka, the Turkish-Japanese hybrid pharmaceutical company, celebrated their five-year anniversary just last year and have ambitions to become the Number One Japanese company in Turkey. Elif Elkin, in her second general manager position, sets out her priorities, comments on the marriage of Turkish and Japanese work practices, and highlights the startlingly low level of CNS disease awareness in Turkey.
How did the affiliate come into being?
“Our dream is to become the Number One Japanese company in Turkey—a market that shows tremendous growth potential. We have great products, and we have a promising launch pipeline."
